Document is current
Any future updates will be listed below
-
Authors
Ardeljan, Daniel
Wang, Xuya
Oghbaie, Mehrnoosh
Taylor, Martin S.
Husband, David
Deshpande, Vikram
Steranka, Jared P.
Gorbounov, Mikhail
Yang, Wan Rou
Sie, Brandon
Larman, H. Benjamin
Jiang, Hua
Molloy, Kelly R.
Altukhov, Ilya
Li, Zhi
McKerrow, Wilson
Fenyö, David
Burns, Kathleen H.
LaCava, John https://orcid.org/0000-0002-6307-7713
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P41GM109824, R01GM126170, P50GM107632)
National Center for Advancing Translational Sciences (UL1TR001866)
Worldwide Cancer Research (19-0223)
National Cancer Institute (U24CA210972)
National Institutes of Health (F30CA221175, R01GM124531, R01GM130680)
- License Information
-
More Information
Article History
Received: 23 August 2019
Accepted: 22 November 2019
First Online: 31 December 2019
Ethics approval and consent to participate
: Formalin fixed paraffin embedded (FFPE) and fresh frozen CRC samples were collected at Massachusetts General Hospital Department of Pathology as de-identified patient samples in accordance with Exemption 4 of research involving human subjects from the NIH.
: Not applicable: no individual person’s data is included in the manuscript.
: Johns Hopkins University has licensed these LINE-1 monoclonal ORF2p antibodies for commercialization to Abcam (Cambridge, UK). D.A., M.S.T., and K.H.B. will receive royalties from sales. K.H.B. and M.S.T. receive royalties from sales of a LINE-1 ORF1p monoclonal antibody licensed to EMD Millipore by Johns Hopkins University.
